my account log out | |
transferrin-Gel immunotoxin |
Create: 03/30/2017 |
Expired Date: | 03/11/2021 |
Category: | Drugs&Pharmaceutical [Health&Medical&Pharmaceutical] |
Message: | This immunotoxin was achieved by conjugating/fusing the transferrin to gelonin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to TFRC expressing cells. Once bind, the toxin enters cells by receptor-mediated endocytosis, then gelonin inhibits protein synthesis by damaging the 60S subunit of mammalian ribosomes. It was designed for treatment of T cell leukemias or lymphomas, graft-versus-host diseases, and autoimmune diseases. |
City: | Shirley[US] |
Location: | |
Feb 01 2023 | VBS++ (with Ca and Mg) Buffer | 214 | |
Feb 01 2023 | GVBE Buffer | 214 | |
Feb 01 2023 | GVB++ (with Ca and Mg) Buffer | 221 | |
Feb 01 2023 | Hemolysin (Rabbit Anti-Sheep Cell Hemolysin) | 208 | |
Aug 30 2019 | Anti-HSV-2 gH Antibody | 392 | |
Aug 30 2019 | Anti-L. major LPG Antibody | 476 | |
Aug 30 2019 | Anti-DENV-1 Antibody | 385 | |
Aug 30 2019 | Anti-BPV-1 L1 Antibody | 401 | |
Aug 30 2019 | Anti-H3N2 HA Antibody | 387 | |
Aug 30 2019 | Anti-EIAV env Antibody | 411 |
Copyright © toextrade Inc. All rights reserved. Contact us |